Log in with your email address username.


[Comment] FGF-19 agonism for NASH: a short study of a long disease

Non-alcoholic steatohepatitis (NASH) has emerged as the most common cause of liver disease worldwide and is on a trajectory to become the most common indication for liver transplantation.1,2 Interest in developing effective therapies for NASH has been proportional. Since its original scientific description, NASH has been a histologically defined disease, characterised by hepatic steatosis and inflammation with variable presence and severity of Mallory’s hyaline, balloon degeneration, and, most important clinically, fibrosis.